<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration </plain></SENT>
<SENT sid="1" pm="."><plain>We have performed a genome-wide association study (GWAS) on 221 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients that had been treated with <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU), either alone or in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX) </plain></SENT>
<SENT sid="2" pm="."><plain>A validation set of 791 patients was also studied </plain></SENT>
<SENT sid="3" pm="."><plain>Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs) </plain></SENT>
<SENT sid="4" pm="."><plain>This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients on a genome-wide scale.The Pharmacogenomics Journal advance online publication, 7 February 2012; doi:10.1038/tpj.2012.2 </plain></SENT>
</text></document>